Related content

Peroxisome Proliferator-Activated Receptors as New Molecular Targets in Psoriasis

By  

Current Drug Targets. Inflammation & Allergy, Vol. 3, Iss. 2, 2004-06 ,pp. : 205-211

Bentham Science Publishers

Access to resources Recommend Favorite

Existing and potential therapeutic approaches targeting peroxisome proliferator-activated receptors in the management of Type 2 diabetes

By Stefanski Dr Adam   Majkowska Liliana  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 12, 2006-12 ,pp. : 1713-1733

Informa Healthcare

Access to resources Recommend Favorite

Peroxisome proliferator activated receptors and obesity

By Kersten S.  

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 223-234

Elsevier

Access to resources Recommend Favorite

Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 1, 2013-02 ,pp. : 70-77

Bentham Science Publishers

Access to resources Recommend Favorite

Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

By Miller Anne R   Etgen Garret J  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1489-1500

Informa Healthcare

Access to resources Recommend Favorite